| Why carry out this study? |
| In pivotal trials, fixed-ratio combination of insulin glargine 100 U/mL and lixisenatide (iGlarLixi) improves metabolic control, with no weight gain and low risk of hypoglycemia in type 2 diabetes (T2D). |
| Data on real-world effectiveness and patterns of use of iGlarLixi are scant. |
| What was learned from the study? |
| Effectiveness and safety of iGlarLixi documented in pivotal trials are confirmed in a real-world setting. |
| However, appropriateness of use and adequate titration should be urgently improved. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.